Inappropriate intensification of glucose-lowering treatment in older patients with type 2 diabetes: the global DISCOVER study
Introduction Although individualized target glycated hemoglobin (HbA1c) levels are recommended in older people with type 2 diabetes, studies report high levels of potential overtreatment. We aimed to investigate the proportion of older patients (aged ≥65 years) who potentially received an inappropri...
Main Authors: | Jesús Medina, Peter Fenici, Fengming Tang, Hirotaka Watada, Antonio Nicolucci, Iichiro Shimomura, Mikhail Kosiborod, Hungta Chen, Andrew Cooper, Brenda Bongaerts, Bernard H Charbonnel, Marilia Gomes, Marina Shestakova |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-08-01
|
Series: | BMJ Open Diabetes Research & Care |
Online Access: | https://drc.bmj.com/content/9/1/e001585.full |
Similar Items
-
Metformin discontinuation in patients beginning second-line glucose-lowering therapy: results from the global observational DISCOVER study programme
by: Peter Fenici, et al.
Published: (2020-08-01) -
Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)
by: Mikhail Kosiborod, et al.
Published: (2018-11-01) -
Type 2 diabetes and heart failure: insights from the global DISCOVER study
by: Suzanne V. Arnold, et al.
Published: (2021-04-01) -
Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
by: Arnold, S.V, et al.
Published: (2022) -
Evidence‐based comparison of glucagon‐like peptide receptor agonists and sodium–glucose cotransporter 2 inhibitors
by: Hirotaka Watada
Published: (2020-01-01)